Navigation Links
NeurogesX to Pursue Expanded U.S. Label for Qutenza® (capsaicin) 8% Patch in HIV-Associated Neuropathy
Date:10/18/2010

i>.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to statements about NeurogesX' plans to submit a supplemental NDA to the FDA and the timing of such submission; expected data to be included in such submission; additional market reach of expanding the Qutenza label to include treatment of pain associated with HIV-AN and the ability to use the U.S. sales force and other relationships to facilitate commercialization of Qutenza in the potential new indication. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: difficulties or delays in the submission of the supplemental NDA for Qutenza; data submitted may not be sufficient to support FDA approval of Qutenza in the treatment of pain associated with HIV-AN; market acceptance of Qutenza in already approved indications may not be sufficient to support further pursuit of an expanded label for Qutenza, including as a result of physician or patient reluctance to use Qutenza; Qutenza and NeurogesX' other product candidates may have unexpected adverse side effects; and potential alternative therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc.

Stephen Ghiglieri

Executive Vice President, COO

and CFO

(650) 358-3310




The Ruth Group

Sara Pellegrino (investor
'/>"/>


SOURCE NeurogesX
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeurogesX to Present at J.P. Morgan Health Care Conference
2. NeurogesX to Present at Piper Jaffray Health Care Conference
3. NeurogesX Reports Third Quarter 2009 Results
4. NeurogesX to Present at Two November Conferences
5. NeurogesX to Present at UBS Global Life Sciences Conference
6. NeurogesX to Present at Upcoming Fall Conferences
7. NeurogesX Appoints New Board Director and Audit Committee Chairman
8. NeurogesX Reports Second Quarter 2009 Results
9. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
10. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
11. NeurogesX Added to Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
(Date:12/24/2014)... Earlier this year in a June 24 international ... Stem Cell Technology Center, LLC ( ASCTC ) focused attention ... adult tissue stem cells. His title “Asymmetric Self-Renewal by ... Future,” embodied the essence of his message to congress participants. ...
(Date:12/24/2014)... 2014 The report provides basic ... classification, application and industry overview. This report also ... structure. Production is separated by regions, technology and ... equipment, downstream client survey, marketing channels, industry development ...
Breaking Biology Technology:Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... owe their existence to a pair of information-carrying molecules: ... features essential for life: they display hereditymeaning they can ... adapt over time, through processes of Darwinian evolution. ... could be performed by molecules other than DNA and ...
... N.C. -- By developing software that uses 3-D models of ... Duke University has identified several new molecules that may ease ... created by the team predict how well a given molecular ... in cystic fibrosis. To test the predictions, the scientists synthesized ...
... based on nanoimprinting techniques (NIL) is evolving at a rapid ... overcome in order to reach the market? How do we ... the industry? What are the tools needed for each product? ... tags to life science products were discussed by more than ...
Cached Biology Technology:Strange cousins: Molecular alternatives to DNA, RNA offer new insight into life's origins 2Strange cousins: Molecular alternatives to DNA, RNA offer new insight into life's origins 3Strange cousins: Molecular alternatives to DNA, RNA offer new insight into life's origins 4Computer-designed molecules point to new therapy for cystic fibrosis 2Computer-designed molecules point to new therapy for cystic fibrosis 3Tackling the European market of nanoimprint lithography 2
(Date:1/22/2015)... YORK , Jan. 22, 2015   EyeLock, Inc. , ... it has appointed Steve Gerber to the new ... will be responsible for leading development of mobile platforms and ... years of success and innovation in the semiconductor industry to ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
(Date:12/19/2014)...  23andMe, Inc., the leading personal genetics company, today announced the ... ancestry of individuals from across the United States ... four hundred years ago, the United States ... different continents. This study illuminates how American history and the ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... KAN. -- An award-winning Kansas State University chemistry professor,s ... him for work on microfluidic devices. Chris Culbertson, ... Horiba Award for "Rapid Analysis of Individual T-Lymphocyte Cells ... Oct. 17, during a special ceremony at Kyoto University ...
... cluster from the silicon up, today announced that the ... teraflop system, will be installed at the U.S. Department ... The lab and its community of researchers will take ... the SC5832 to conduct research in a variety of ...
... Meeting) - October 15, 2007 - The pregnancy rate ... doctors use advanced 3D/4D imaging to guide the placement ... most receptive to implantation, according to a study presented ... for Reproductive Medicine (ASRM). Placing embryos in ...
Cached Biology News:K-State chemistry professor to receive Masao Horiba award 2Argonne National Lab acquires first SiCortex SC5832 2In-vitro fertilization improved with 3-D/4-D-guided embryo transfer and new placement target 2In-vitro fertilization improved with 3-D/4-D-guided embryo transfer and new placement target 3